Subchronic fluoxetine treatment induces a transient potentiation of amphetamine-induced hyperlocomotion: Possible pharmacokinetic interaction

Behavioural Pharmacology

Volumn 11, Issue 2, 2000, Pages 109-116

  Sills, T L ^a   Greenshaw, A J ^b   Baker, G B ^b   Fletcher, P J ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cytochrome P450; Fluoxetine; Locomotion; Sensitization; SSRI; Wistar rat

Indexed keywords

AMPHETAMINE; CYTOCHROME P450; FLUOXETINE; NORFLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; DRUG ACTIVATION; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; RAT; SENSITIZATION; TREATMENT OUTCOME;

EID: 0034078627     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200004000-00002     Document Type: Article

References (32)

1. Al-Dabbagh SG, Idle JR, Smith RL (1981). Animal modeling of human polymorphic drug oxidation: the metabolism of debrisoquine and pheacetin in rat inbred strains. J Pharm Pharmacol 33:1116-1164.
2. Arnt J, Hyttel J, Overo KF (1984). Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions. Pol J Pharmacol Pharm 36:221-230.
3. Brown EE, Nomikos GG, Wilson C, Fibiger HC (1991). Chronic desipramine enhances the effect of locally applied amphetamine on interstitial concentrations of dopamine in the nucleus accumbens. Eur J Pharmacol 202:125-127.
4. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992). The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver microsomes. Br J Clin Pharmacol 34:262-265.
5. Gardier AM, Lepoul E, Trouvin JH, Chanut E, Dessalles MC, Jacquot C (1994). Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci 54:PL51-56.
6. Ichikawa J, Kuroki T, Meltzer HY (1998). Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens. Eur J Pharmacol 350:159-164.
7. Lane RM (1996). Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 11:31-61.
8. Law MYL, Moody DE (1994). Urinary excretion of amphetamine and 4′-hydroxyamphetamine by Sprague Dawley and Dark Agouti rats. Life Sci 54:1073-1079.
9. Maj J. Wedzony K (1985). Repeated treatment with imipramine or amitriptyline increases the locomotor response of rats to (+)-amphetamine given into the nucleus accumbens. J Pharm Pharmacol 37:362-364.
10. Maj J, Rogoz Z, Skuza G, Sowinska H (1984). Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine. J Pharm Pharmacol 36:127-130.
11. Masubuchi Y, Takahashii C, Fujio N, Horie T, Suzuki T, Imaoka S, Funae Y, Narimatsu S (1995). Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats. Drug Metab Dispos 23:999-1003.
12. Moody DE, Ruangyuttikarn W, Law MY (1990). Quinidine inhibits in vivo metabolism of amphetamine in rats: impact upon correlation between GC/MS and immunoassay findings in rat urine. J Anal Toxicol 14:311-317.
13. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1991). Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens. Eur J Pharmacol 195:63-73.
14. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM (1993). Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin Pharmacol Ther 53:401-409.
15. Preskorn S (1994). Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 9 (suppl 3):13-19.
16. Richelson E (1997). Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 72:835-847.
17. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 11:157-198.
18. Rotzinger S, Todd KG, Bourin M, Coutts RT, Baker GB (1997). A rapid electron-capture gas chromatographic method for the quantification of fluvoxamine in brain tissue. J Pharmacol Toxicol Methods 37:129-133.
19. Rudorfer MV, Potter WZ (1999). Metabolism of tricyclic anti-depressants. Cell Mol Neurobiol 19:373-409.
20. Segal DS, Kuczenski R (1987). Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J Pharmacol Exp Ther 242:917-926.
21. Segal DS, Weinberger SB, Cahill J, McCunney SJ (1980). Multiple daily amphetamine administration: behavioral and neurochemical alterations. Science 207:904-906.
22. Sequeira DJ, Strobel HW (1996). In vitro metabolism of imipramine by brain microsomes: effects of inhibitors and exogenous cytochrome P450 reductase. Brain Res 738:24-31.
23. Shah K, Bradshaw CM, Szabadi E (1990). Interaction between antidepressants and d-amphetamine on variable-interval performance. Psychopharmacology 100:548-554.
24. Shen WW(1997). The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition. Biol Psychiatry 41:814-826.
25. Sills TL, Vaccarino FJ (1994). Individual differences in sugar intake predict the locomotor response to acute and repeated amphetamine administration. Psychopharmacology 116:1-8.
26. Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ (1999a). Acute fluoxetine treatment potentiates amphetamine-hyperactivity and amphetamine-induced nucleus accumbens-dopamine release: possible pharmacokinetic interaction. Psychopharmacology 141:421-427.
27. Sills TL, Greenshaw A, Baker GB, Fletcher P (1999b). The potentiating effect of sertraline and fluoxetine on amphetamine-induced locomotor activity is not mediated by serotonin. Psychopharmacology 143:426-432.
28. Spyraki C, Fibiger HC (1981). Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol 74:195-206.
29. Stewart J, Rajabi H (1996). Initial increases in extracellular dopamine in the ventral tegmental area provide a mechanism for the development of desipramine-induced sensitization within the midbrain dopamine system. Synapse 23:258-264.
30. Strobel HW, Kawashima H, Geng J, Sequeira D, Bergh A, Hodgson AV, Wang H, Shen S (1995). Expression of multiple forms of brain cytochrome P450. Toxicol Lett 82-83:639-643.
31. Towell A, Willner P, Booth DA (1985). Central and peripheral contributions to the enhancement of amphetamine anorexia by desmethylimipramine (DMI). Pharmacol Biochem Behav 22:57-60.
32. Willner P (1984). The validity of animal models of depression. Psychopharmacology 83:1-16.